BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lang H, Béraud C, Bethry A, Danilin S, Lindner V, Coquard C, Rothhut S, Massfelder T. Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma. Oncotarget 2016;7:59336-59. [PMID: 27449081 DOI: 10.18632/oncotarget.10659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Tracey AT, Murray KS, Coleman JA, Kim K. Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma. Cancers (Basel) 2020;12:E439. [PMID: 32069881 DOI: 10.3390/cancers12020439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 van de Merbel AF, van der Horst G, van der Pluijm G. Patient-derived tumour models for personalized therapeutics in urological cancers. Nat Rev Urol 2021;18:33-45. [PMID: 33173206 DOI: 10.1038/s41585-020-00389-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Pohl L, Friedhoff J, Jurcic C, Teroerde M, Schindler I, Strepi K, Schneider F, Kaczorowski A, Hohenfellner M, Duensing A, Duensing S. Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. Front Oncol 2022;12:889686. [PMID: 35619925 DOI: 10.3389/fonc.2022.889686] [Reference Citation Analysis]
4 Beserra AO, Estevan EC, Bezerra SM, Torrezan GT, Ikegami A, Dellê H, Cunha IW, Meira IT, Carraro DM, Lara PN, Zequi SC, Martins VR, Santos TG. Patient-Derived Renal Cell Carcinoma Xenografts Capture Tumor Genetic Profiles and Aggressive Behaviors. KCA 2022. [DOI: 10.3233/kca-210011] [Reference Citation Analysis]
5 Inoue T, Terada N, Kobayashi T, Ogawa O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol. 2017;14:267-283. [PMID: 28248952 DOI: 10.1038/nrurol.2017.19] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
6 Roelants C, Pillet C, Franquet Q, Sarrazin C, Peilleron N, Giacosa S, Guyon L, Fontanell A, Fiard G, Long JA, Descotes JL, Cochet C, Filhol O. Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. Cancers (Basel) 2020;12:E232. [PMID: 31963500 DOI: 10.3390/cancers12010232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
7 Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R, Lundin J, Järvinen P, Nisen H, Taari K, Af Hällström TM, Rannikko A, Mirtti T, Kallioniemi O, Östling P. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. Int J Cancer 2019;144:1356-66. [PMID: 30125350 DOI: 10.1002/ijc.31815] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
8 Wang CF, Shi XJ. Generation and application of patient-derived xenograft models in pancreatic cancer research. Chin Med J (Engl) 2019;132:2729-36. [PMID: 31725451 DOI: 10.1097/CM9.0000000000000524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Gürgen D, Becker M, Dahlmann M, Flechsig S, Schaeffeler E, Büttner FA, Schmees C, Bohnert R, Bedke J, Schwab M, Wendler JJ, Schostak M, Jandrig B, Walther W, Hoffmann J. A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. Front Oncol 2022;12:889789. [DOI: 10.3389/fonc.2022.889789] [Reference Citation Analysis]
10 Zhang F, Wang W, Long Y, Liu H, Cheng J, Guo L, Li R, Meng C, Yu S, Zhao Q, Lu S, Wang L, Wang H, Wen D. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun (Lond) 2018;38:60. [PMID: 30257718 DOI: 10.1186/s40880-018-0329-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
11 Sobczuk P, Brodziak A, Khan MI, Chhabra S, Fiedorowicz M, Wełniak-Kamińska M, Synoradzki K, Bartnik E, Cudnoch-Jędrzejewska A, Czarnecka AM. Choosing The Right Animal Model for Renal Cancer Research. Transl Oncol 2020;13:100745. [PMID: 32092671 DOI: 10.1016/j.tranon.2020.100745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
12 Lee AQ, Ijiri M, Rodriguez R, Gandour-Edwards R, Lee J, Tepper CG, Li Y, Beckett L, Lam K, Goodwin N, Satake N. Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib. Front Oncol 2021;11:648097. [PMID: 33842362 DOI: 10.3389/fonc.2021.648097] [Reference Citation Analysis]
13 Li L, Niu H, Sun B, Xiao Y, Li W, Yuan H, Lou H. Riccardin D-N induces lysosomal membrane permeabilization by inhibiting acid sphingomyelinase and interfering with sphingomyelin metabolism in vivo. Toxicol Appl Pharmacol 2016;310:175-84. [PMID: 27660101 DOI: 10.1016/j.taap.2016.09.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
14 Druzhkova IN, Shirmanova MV, Kuznetsova DS, Lukina ММ, Zagaynova ЕV. Modern Approaches to Testing Drug Sensitivity of Patients' Tumors (Review). Sovrem Tekhnologii Med 2021;12:91-102. [PMID: 34795997 DOI: 10.17691/stm2020.12.4.11] [Reference Citation Analysis]
15 Okada S, Vaeteewoottacharn K, Kariya R. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Cells 2019;8:E889. [PMID: 31412684 DOI: 10.3390/cells8080889] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]